Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

on behalf of the C4591054 Study Group

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial'. Together they form a unique fingerprint.

Keyphrases

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology